目的 探討百樂眠膠囊聯(lián)合艾司唑侖治療失眠癥的臨床療效。方法 選取2016-2018年到云浮市人民醫(yī)院接受治療的210例失眠癥患者，根據(jù)給藥不同將所有患者分為3組，每組患者70例。百樂眠組口服百樂眠膠囊，4粒/次，2次/d；艾司唑侖組晚上入睡前30 min口服艾司唑侖片，1片/次，1次/d；聯(lián)合組口服百樂眠膠囊聯(lián)合艾司唑侖片，相關(guān)藥物服用方法同以上兩組。三組患者均連續(xù)治療2周。觀察三組的臨床療效，比較三組患者匹茲堡睡眠質(zhì)量指數(shù)（PSQI）和不良反應(yīng)發(fā)生情況。結(jié)果 治療后，百樂眠組、艾司唑侖組、聯(lián)合組總有效率分別是74.28%、82.86%、97.14%，聯(lián)合組總有效率顯著高于百樂眠組、艾司唑侖組，差異有統(tǒng)計學(xué)意義（P<0.05）。治療后，3組患者PSQI評分均有所降低（P<0.05）；但治療后，聯(lián)合組患者PSQI各評分均顯著低于百樂眠組、艾司唑侖組（P<0.05）。百樂眠組、艾司唑侖組、聯(lián)合組不良反應(yīng)發(fā)生率分別是8.57%、22.86%、10.00%，艾司唑侖組失眠癥患者不良反應(yīng)發(fā)生率明顯高于百樂眠組、聯(lián)合組（P<0.05）。結(jié)論 百樂眠膠囊聯(lián)合艾司唑侖治療失眠癥具有較好的臨床療效，可顯著降低PSQI評分，改善患者睡眠質(zhì)量，具有一定的臨床推廣應(yīng)用價值。

Objective To analysis the effect of Bailemian Capsules combined with estazolam in treatment of insomnia. Methods 210 Patients with insomnia treated in Yunfu People's Hospital from 2016 to 2018 were divided into 3 groups according to the different medication methods, and 70 patients in each group. Patients in Bailemian group were po administered with Bailemian Capsules, 4 grains/time, twice daily. Patients in estazolam group were po administered with Estazolam Tablets 30 min before falling asleep at night, 1 tablet/time, once daily. Patients in combination group were po administered with Bailemian Capsules and Estazolam Tablets, and the drug administration methods were the same as the above two groups. Patients in all three groups were treated for 2 weeks. The clinical efficacy of the three groups were observed, PSQI and adverse reactions were compared. Results After treatment, the total effective rates of the Bailemian group, estolam group and the combination group were 74.28%, 82.86% and 97.14%, respectively. The total effective rates of the combination group were significantly higher than that of Bailemian group and estolam group, with statistically significant differences (P<0.05). After treatment, the PSQI scores of all three groups were decreased (P<0.05). However, after treatment, the PSQI scores of the combination group were significantly lower than that of the Bailemian group, the estolam group (P<0.05). The incidence of adverse reactions was 8.57%, 22.86% and 10.00%, respectively, in the Bailemian group, the estolam group and the combination group. The incidence of adverse reactions in the estolam group was significantly higher than that in the Bailemian group and the combination group (P<0.05). Conclusion Bailemian Capsules combined with estazolam has good clinical effect in treatment of insomnia, and can significantly reduce the PSQI score, improve the sleep quality of patients, which has a certain clinical application value.

R971

云浮市衛(wèi)生健康局項(xiàng)目-百樂眠膠囊聯(lián)合艾司唑侖治療失眠的臨床觀察（2017B09）